On August 11, GENSCRIPT BIO rose 3.23% in regular trading, trading at 24.98 HKD/share, with turnover of HKD 162 million, extending its recent strong performance.

On the news front, multiple positive catalysts continue to drive the stock. Global AI-driven drug discovery is entering its commercialization phase, with US-listed Twist Bioscience reporting mid-year results that beat expectations and AI-related orders doubling year-over-year. GENSCRIPT BIO's life sciences division covers DNA synthesis, protein production, antibody development, and functional validation, positioning it as a key infrastructure provider converting AI-generated sequences into physical proteins and experimental data. The life sciences division recorded revenue of USD 522 million, up 14.8% year-over-year.

Additionally, associate Legend Biotech reported CARVYKTI Q2 net trade sales of USD 657 million, up 49.4% year-over-year, with first-half sales reaching USD 1.254 billion, up 55.1%. The company is set to hold a board meeting on August 15 to review interim results and dividend arrangements, further boosting market expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)